Valuation pains in the wave of AI? Mizuho "slashes three times": lowers target prices for Atlassian (TEAM.US), Cloudflare (NET.US), and Microsoft Corporation (MSFT.US)
On Wednesday, the investment firm Mizuho Securities lowered its target stock prices for several technology companies, making Atlassian (TEAM.US), Cloudflare (NET.US), and Microsoft (MSFT.US) the focus of market attention.
On Wednesday, the investment firm Mizuho Securities lowered the target stock prices for several technology companies, making Atlassian (TEAM.US), Cloudflare (NET.US), and Microsoft Corporation (MSFT.US) the focus of the market.
Mizuho lowered Atlassian's target price from $245 to $225, Cloudflare's target price from $280 to $255, and Microsoft Corporation's target price from $640 to $620. The firm maintained an "outperform" rating for these three companies.
Analyst Gregg Moskowitz stated in a client report, "Our market research in the fourth quarter overall showed solid performance. Public cloud/consumer data points were generally good, and demand for AI applications remains very strong. Network security demand is healthy, and the SaaS sector also showed resilience.
However, it should be noted that some research indicates a slight easing in year-end budget releases compared to usual. In addition, investors' continued concerns about industry disruption caused by AI continue to suppress the valuation multiples of many software companies, with the SaaS sector particularly affected."
Moskowitz further analyzed, "From a valuation perspective, the enterprise value-to-sales multiple for the next twelve months is 55% lower than the five-year peak and 30% lower than the average level. We believe the risk-return ratio for the next twelve months is attractive, but higher uncertainty may bring unusual challenges and volatility."
The firm stated that, overall, the stocks they are most bullish on before the earnings season are Atlassian and Microsoft Corporation.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


